Valganciclovir appeared to provide a survival advantage also in patients with GBM with an unmethylated MGMT promoter: treated patients (n = 11) survived a median of 13.3 months after recurrence compared to 6.2 months of the controls (n = 23) (p = 0.0076) (Figure 3B). The gene discussed is MGMT; the disease is glioblastoma.